Omeros CEO Gets Options On 500,000 Shares That Pay Only If Stock Hits $25
The award has four price hurdles topping out at $40.00, a $17.88 exercise price and a five-year term, the company said.
Omeros, the biotech company behind the transplant-complication drug YARTEMLEA, granted CEO Gregory Demopulos performance-based options on up to 500,000 shares on Wednesday, the company disclosed in an 8-K filed Friday. Nothing vests unless the stock climbs well above its $17.88 grant-date close and he stays on.
Four price hurdles, five years
The Compensation Committee split the award equally across four tranches. Each unlocks only when the stock's volume-weighted average price, measured over 30 consecutive trading days as a single period, reaches $25.00, $30.00, $35.00 or $40.00 at any point in the five-year term.
The exercise price is $17.88, the closing price on the grant date. The company said the hurdles represent appreciation of about 40%, 68%, 96% and 124% above that level.
A service clock runs alongside the price test. Of each tranche, 25% becomes eligible to vest on the first anniversary of the grant, and the rest vests in equal monthly installments over the following 36 months. No portion was vested and no shares were issued on the grant date, and the award expires October 28, 2031.
Why the board says he earned it
The committee pointed to Demopulos's role in driving what it called transformative change in 2025. That included winning FDA approval of YARTEMLEA, completing the sale of zaltenibart to Novo and carrying out a series of transactions to strengthen the balance sheet.
It also noted that his long-term equity awards and target total direct compensation for 2025 significantly trailed the company's peers. The committee built the structure with an independent compensation consultant's market analysis of similar awards, and said it should push him to drive "meaningful and sustained stock price appreciation."
What happens in a sale of the company
In a change in control, the per-share deal price replaces the trading-average test. Any tranche whose hurdle sits above that price is forfeited.
A tranche that has met the price test but not the service condition vests fully if Demopulos is fired without cause or is constructively terminated in connection with the change in control or within 12 months afterward.
Omeros develops protein and small-molecule drugs aimed at complement-driven diseases, cancers and addictive or compulsive disorders. YARTEMLEA, approved December 23, 2025, treats a stem cell transplant complication called TA-TMA and is its only commercial product. In November 2025 it sold zaltenibart to Novo Nordisk for a $240.0 million upfront payment.
The first hurdle, $25.00, has to hold as a 30-trading-day average before any of the options can vest, and the award runs through October 28, 2031.
Sources
- 8-K Filing — OMEROS CORP (OMER) — SEC EDGAR